drugset / Trial / NCT03585426

Vancomycin in the Target Site Treatment of Intracranial Infection

NCT03585426

Phase 4 Unknown 2 enrolled Xijing Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Vancomycin, a novel intravenously administered antibiotic, currently plays a key role in the management of complicated multi-organism infections. However,current LC-MS/MS methods briefly describe parameters and the only reported internal standard was sometimes difficult to obtain. In our study,an updated LC-MS/MS method for the quantitative analysis of vancomycin in human serum was developed.

Timeline

Start
2016-03
Primary completion
2018-12
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Vancomycin Other / unclassified 1 g Intravenous

Indications

No indication recorded.